a 2023 aiding unlicensed practice citation at Salt Lake City)
M.ArnoldM.GrillH
Therapeutic Advances in Endocrinology and Metabolism
Call both: (1) your HR department and (2) the number on your card
2022 DOI: 10.1016/j.cmet.2022.07.013 PMID: 35985340 Read on PubMed The Lancet LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial Urva S, Coskun T, Loh MT, et al
Other Therapies: Physical therapy, vision therapy, or referrals to collaborating care when needed